National Public Health Burden Estimates of Endocarditis and Skin and Soft-Tissue Infections Related to Injection Drug Use: A Review.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
02 09 2020
Historique:
entrez: 3 9 2020
pubmed: 3 9 2020
medline: 19 3 2021
Statut: ppublish

Résumé

Despite concerns about the burden of the bacterial and fungal infection syndromes related to injection drug use (IDU), robust estimates of the public health burden of these conditions are lacking. The current article reviews and compares data sources and national burden estimates for infective endocarditis (IE) and skin and soft-tissue infections related to IDU in the United States. A literature review was conducted for estimates of skin and soft-tissue infection and endocarditis disease burden with related IDU or substance use disorder terms since 2011. A range of the burden is presented, based on different methods of obtaining national projections from available data sources or published data. Estimates using available data suggest the number of hospital admissions for IE related to IDU ranged from 2900 admissions in 2013 to more than 20 000 in 2017. The only source of data available to estimate the annual number of hospitalizations and emergency department visits for skin and soft-tissue infections related to IDU yielded a crude estimate of 98 000 such visits. Including people who are not hospitalized, a crude calculation suggests that 155 000-540 000 skin infections related to IDU occur annually. These estimates carry significant limitations. However, regardless of the source or method, the burden of disease appears substantial, with estimates of thousands of episodes of IE among persons with IDU and at least 100 000 persons who inject drugs (PWID) with skin and soft-tissue infections annually in the United States. Given the importance of these types of infections, more robust and reliable estimates are needed to better quantitate the occurrence and understand the impact of interventions.

Sections du résumé

BACKGROUND
Despite concerns about the burden of the bacterial and fungal infection syndromes related to injection drug use (IDU), robust estimates of the public health burden of these conditions are lacking. The current article reviews and compares data sources and national burden estimates for infective endocarditis (IE) and skin and soft-tissue infections related to IDU in the United States.
METHODS
A literature review was conducted for estimates of skin and soft-tissue infection and endocarditis disease burden with related IDU or substance use disorder terms since 2011. A range of the burden is presented, based on different methods of obtaining national projections from available data sources or published data.
RESULTS
Estimates using available data suggest the number of hospital admissions for IE related to IDU ranged from 2900 admissions in 2013 to more than 20 000 in 2017. The only source of data available to estimate the annual number of hospitalizations and emergency department visits for skin and soft-tissue infections related to IDU yielded a crude estimate of 98 000 such visits. Including people who are not hospitalized, a crude calculation suggests that 155 000-540 000 skin infections related to IDU occur annually.
DISCUSSION
These estimates carry significant limitations. However, regardless of the source or method, the burden of disease appears substantial, with estimates of thousands of episodes of IE among persons with IDU and at least 100 000 persons who inject drugs (PWID) with skin and soft-tissue infections annually in the United States. Given the importance of these types of infections, more robust and reliable estimates are needed to better quantitate the occurrence and understand the impact of interventions.

Identifiants

pubmed: 32877563
pii: 5900610
doi: 10.1093/infdis/jiaa149
pmc: PMC8112118
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S429-S436

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI070114
Pays : United States

Informations de copyright

Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Références

JAMA. 2012 Apr 4;307(13):1405-13
pubmed: 22474204
Int J Drug Policy. 2017 Jan;39:21-27
pubmed: 27768990
Am J Public Health. 2019 May;109(5):784-791
pubmed: 30896999
J Am Coll Cardiol. 2019 Feb 12;73(5):559-570
pubmed: 30732709
MMWR Morb Mortal Wkly Rep. 2017 Jun 09;66(22):569-573
pubmed: 28594786
Health Aff (Millwood). 2016 May 1;35(5):832-7
pubmed: 27140989
BMJ Open. 2018 Jun 19;8(6):e020857
pubmed: 29921683
JAMA. 2017 Oct 3;318(13):1241-1249
pubmed: 28903154
J Am Coll Cardiol. 2018 Apr 10;71(14):1596-1597
pubmed: 29622169
Emerg Infect Dis. 2015 Sep;21(9):1499-509
pubmed: 26289824
BMC Infect Dis. 2013 Apr 10;13:171
pubmed: 23574801
Open Forum Infect Dis. 2016 Jul 26;3(3):ofw157
pubmed: 27800528
Drug Alcohol Depend. 2018 Jun 1;187:8-12
pubmed: 29626746
MMWR Morb Mortal Wkly Rep. 2019 Apr 19;68(15):344-349
pubmed: 30998671
Emerg Infect Dis. 2018 Apr;24(4):
pubmed: 29553923
PLoS One. 2014 May 19;9(5):e97596
pubmed: 24840662
Infect Dis Ther. 2019 Mar;8(1):113-118
pubmed: 30673991
Am J Prev Med. 2019 May;56(5):639-647
pubmed: 30851991
Med Care. 2007 Oct;45(10 Supl 2):S96-102
pubmed: 17909391
MMWR Morb Mortal Wkly Rep. 2019 Mar 01;68(8):205-206
pubmed: 30817749
Am J Med Sci. 2016 Dec;352(6):603-608
pubmed: 27916215
Med Care. 2018 Oct;56(10):e70-e75
pubmed: 29200131
MMWR Morb Mortal Wkly Rep. 2019 Jul 05;68(26):583-586
pubmed: 31269011
Ann Intern Med. 2019 Jan 1;170(1):31-40
pubmed: 30508432
N Engl J Med. 2016 Jul 21;375(3):229-39
pubmed: 27468059
Am J Public Health. 2018 Feb;108(2):175-181
pubmed: 29267061
Int J Drug Policy. 2018 May;55:31-39
pubmed: 29482150
N Engl J Med. 2018 Mar 29;378(13):1169-1171
pubmed: 29601263
J Community Health. 2018 Jun;43(3):598-603
pubmed: 29305727
MMWR Morb Mortal Wkly Rep. 2019 Mar 29;68(12):285-288
pubmed: 30921302
JAMA. 2017 Apr 25;317(16):1652-1660
pubmed: 28444279
NCHS Data Brief. 2018 Nov;(329):1-8
pubmed: 30500323
Subst Abus. 2017 Jan-Mar;38(1):105-112
pubmed: 27897966
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):625-628
pubmed: 29879096

Auteurs

Isaac See (I)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Runa H Gokhale (RH)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Andrew Geller (A)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Maribeth Lovegrove (M)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Asher Schranz (A)

Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.

Aaron Fleischauer (A)

North Carolina Department of Health, Raleigh, North Carolina, USA.
Career Epidemiology Field Officer, Centers for Disease Control and Prevention, Atlanta, Georgia, UA.

Natalie McCarthy (N)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

James Baggs (J)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Anthony Fiore (A)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH